MSc EMBA - Argenx NV CEO Director

ARGX Stock  USD 623.82  2.21  0.35%   

CEO

MSc EMBA is CEO Director of argenx NV ADR
Age 52
Address Laarderhoogtweg 25, Amsterdam, Netherlands, 1101EB
Phone31 10 703 8441
Webhttps://www.argenx.com

Argenx NV Management Efficiency

The company has return on total asset (ROA) of (0.0551) % which means that it has lost $0.0551 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0574) %, meaning that it created substantial loss on money invested by shareholders. Argenx NV's management efficiency ratios could be used to measure how well Argenx NV manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Argenx NV's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 439.7 M in 2024, whereas Other Current Assets are likely to drop slightly above 113.9 M in 2024.
argenx NV ADR currently holds 20 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. argenx NV ADR has a current ratio of 10.85, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Argenx NV's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 7 records

CEO Age

Andrew MDAkero Therapeutics
57
MBChB MBAAlnylam Pharmaceuticals
61
Jeremy MBADay One Biopharmaceuticals
53
Amy MBATerns Pharmaceuticals
54
Kathryn MBABlueprint Medicines Corp
48
Jan MikkelsenAscendis Pharma AS
64
Eric DubeTravere Therapeutics
51
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Ltd, Universit Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands. Argenx Se is traded on NASDAQ Exchange in the United States. argenx NV ADR (ARGX) is traded on NASDAQ Exchange in USA. It is located in Laarderhoogtweg 25, Amsterdam, Netherlands, 1101EB and employs 1,148 people. Argenx NV is listed under Biotechnology category by Fama And French industry classification.

Management Performance

argenx NV ADR Leadership Team

Elected by the shareholders, the Argenx NV's board of directors comprises two types of representatives: Argenx NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Argenx. The board's role is to monitor Argenx NV's management team and ensure that shareholders' interests are well served. Argenx NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Argenx NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
Karen Massey, Chief Officer
Beth DelGiacco, VP Relations
EMBA MBA, CEO Director
Filip Borgions, VP Operations
Arjen MSc, Vice Strategy
Karl Gubitz, Chief Officer
Luc Truyen, Chief Officer
Malini Moorthy, General Counsel
MSc EMBA, CEO Director
Peter Ulrichts, Chief Officer
Pr Ir, CoFounder Officer
Keith Woods, Chief Officer
David MD, Advisor
Andria Wilk, Global Quality
Marc Schorpion, Global Resources

Argenx Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Argenx NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Argenx Stock Analysis

When running Argenx NV's price analysis, check to measure Argenx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Argenx NV is operating at the current time. Most of Argenx NV's value examination focuses on studying past and present price action to predict the probability of Argenx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Argenx NV's price. Additionally, you may evaluate how the addition of Argenx NV to your portfolios can decrease your overall portfolio volatility.